XNAS
ENVB
Market cap6mUSD
Oct 08, Last price
1.52USD
1D
1.67%
1Q
12.59%
Jan 2017
-100.00%
IPO
-100.00%
Name
Enveric Biosciences Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
103.51%
Rev. gr., 5y
20.09%
Revenues
0
Net income
-12m
L+26.70%
CFO
-8m
L+5.38%
Dividend
Apr 23, 20080.021 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Key people
Michael Webb
Independent Chairman of the Board · since 2022
Joseph Tucker
Chief Executive Officer, Director · since 2021
Kevin Coveney
Chief Financial Officer · since 2023
Chief Innovation Officer · since 2021
Sheila DeWitt
Independent Director · since 2024
George Kegler
Independent Director · since 2020
Frank Pasqualone
Independent Director · since 2022
Marcus Schabacker
Independent Director · since 2020
Michael Webb
Independent Chairman of the Board · since 2022
Legal address
C/O Delaware Corporation Organizers, Inc.
PO Box 1347
18th Floor
1201 North Market Street
Wilmington, DE 19801
US
PO Box 1347
18th Floor
1201 North Market Street
Wilmington, DE 19801
US
Headquarters
1st Floor
53 Forest Avenue
Old Greenwich, CT 06870
US
53 Forest Avenue
Old Greenwich, CT 06870
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||